Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech plunges on drug side effects
Puma Biotechnology
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology a Buy? | The Motley Fool
SEC charges former Puma biotech exec with $1.1 million in insider trading
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotechnology
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology Shares Dropped 17.7% This Week | The Motley Fool
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
